Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Illumina Inc. (ILMN - Analyst Report) announced the signing of a multi-year supply deal with Laboratory Corp. of America Holdings (LH - Analyst Report). With the agreement, LH gained expanded rights to use ILMN’s next-generation sequencing (NGS) platform, and microarray equipment and supplies to develop and market laboratory-developed tests. The financial details of the transaction, however, remain undisclosed.

The expanded deal will now allow Laboratory Corp. access to a wide range of Illumina’s products to develop innovative diagnostic tools. The focus will be on enhancing treatment in multiple areas like genetic testing, oncology and medicine, and forensics transplant.

Last week, ILMN announced plans to enter emerging markets in mid-2014 by launching a human leukocyte antigen (HLA) typing product, developed using its NGS platform. The HLA typing assays that LH will develop based on the NGS platform will enable physicians to accurately match bone marrow donors to recipients.

However, Laboratory Corp. will market these tests in the U.S. and Canada. Thus, the agreement seems to be in tandem with Illumina’s mission to enhance cancer research and treatments by expanding the use of the NGS platform.

Next generation sequencing is a hi-tech platform designed to perform advanced research on DNA or RNA molecules. We believe the NGS platform offers great market potential. The LH deal is in line with ILMN’s efforts to strengthen its presence in this space.

Earlier this month, Illumina signed an agreement with Amgen Inc. (AMGN - Analyst Report) to develop and market a multigene NGS based test to be used as a companion diagnostic for Amgen’s cancer treatment, Vectibix. In the same month, ILMN also entered into a strategic partnership with Quest Diagnostics Inc. (DGX - Analyst Report) allowing the latter to use its MiseqDX platform and related reagents for molecular laboratory-developed tests.

We are optimistic about Illumina’s expansion strategy through the enhancement of its portfolio of sequencing products, and development of strategic partnerships with therapeutics and diagnostic services providers. Currently, ILMN has a Zacks Rank #3 (Hold).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%